<DOC>
	<DOCNO>NCT00928434</DOCNO>
	<brief_summary>The purpose study see give Degarelix every month 7 month stop treatment 7 month ( intermittent therapy ) would show reduction negative effect androgen deprivation therapy increase quality life keep prostate specific antigen ( PSA ) level suppress .</brief_summary>
	<brief_title>A Study Degarelix Patients With Prostate Cancer</brief_title>
	<detailed_description>This open-label , randomize , parallel-arm , multicenter study determine degarelix intermittent therapy non-inferior continuous androgen deprivation therapy ( combination treatment group receive continuous degarelix leuprolide therapy , respectively ) maintain PSA level ≤ 4.0 ng/mL 14 month . The study consist two phase , Phase A B . During Phase A , patient degarelix intermittent degarelix continuous arm receive 7 month therapy degarelix one-month depot formulation patient leuprolide continuous arm receive leuprolide one-month depot injection ( 7.5 mg ) follow two 3-month depot ( 22.5 mg ) injection . After 7 month treatment , patient PSA ≤2 ng/mL continue Phase B . During Phase B , patient degarelix intermittent arm 7-month off-treatment period . Patients randomize degarelix continuous arm leuprolide continuous arm continue receive degarelix leuprolide depot Phase A remainder 14 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>18 year old . Raising PSA prior treatment failure localize prostate cancer . Has histological confirm nonmetastatic cancer prostate ( Gleason grade ) base current biopsy . Has screen testosterone within normal range ( ≥1.5 ng/mL ) . Has Eastern Cooperative Oncology Group score ≤2 . Bone scan CT scan report document evidence metastasis bone internal organ . Life expectancy least 15 month . Taken hormone therapy last 6 month prior enter study . Being treat 5alpha reductase inhibitor time enrolment remain stable dose throughout trial . Has history severe uncontrolled asthma , anaphylactic reaction , severe urticaria and/or angioedema . Has hypersensitivity towards component study drug . Has previous history presence another malignancy prostate cancer treat squamous/basal cell carcinoma skin within last five year . Has abnormal laboratory result judgement Investigator would affect patient 's health outcome trial . Has clinically significant medical condition ( prostate cancer ) include limit ; renal , haematological , gastrointestinal , endocrine , cardiac , neurological psychiatric disease alcohol drug abuse condition may affect patient 's health outcome trial judge Investigator . Has intellectual incapacity language barrier preclude adequate understanding cooperation . Has receive investigational drug within last 28 day Screening visit longer consider possibly influence outcome current trial . Has receive ketoconazole diflucan last 28 day precede Screening Visit . Has previously participate Degarelix trial . Is part ongoing trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>